| scholarly article | Q13442814 |
| P50 | author | Thomas Quertermous | Q28805357 |
| Nicholas J. Leeper | Q92979518 | ||
| P2093 | author name string | Euan A Ashley | |
| Michael J Lenardo | |||
| Yoko Kojima | |||
| Ahmad Y Sheikh | |||
| Andrew J Patterson | |||
| Hyung J Chun | |||
| Joshua P Anderson | |||
| Lixin Zheng | |||
| Nathan E Pearl | |||
| Philip S Tsao | |||
| Ramendra K Kundu | |||
| Rani Agrawal | |||
| Ziad A Ali | |||
| P2860 | cites work | Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor | Q22004174 |
| AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration | Q24290268 | ||
| A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11 | Q24336729 | ||
| The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo | Q24643958 | ||
| Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression | Q24679740 | ||
| Characterization of apelin, the ligand for the APJ receptor | Q28141574 | ||
| APJ Receptor mRNA Expression in the Rat Hypothalamic Paraventricular Nucleus: Regulation By Stress and Glucocorticoids | Q28184941 | ||
| The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism | Q28198114 | ||
| Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility | Q28221294 | ||
| Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo | Q28256865 | ||
| Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity | Q28301433 | ||
| Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells | Q28303724 | ||
| Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release | Q28569332 | ||
| Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats | Q28583950 | ||
| Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E | Q29615236 | ||
| In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure | Q30484162 | ||
| Measurement of molecular interactions in living cells by fluorescence resonance energy transfer between variants of the green fluorescent protein | Q30782936 | ||
| Environmental-dependent acceleration of a developmental switch: the floral transition | Q33336723 | ||
| A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling | Q33907802 | ||
| Genetic modifiers of atherosclerosis in mice | Q34080318 | ||
| The angiotensin II AT2 receptor is an AT1 receptor antagonist. | Q34086986 | ||
| Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice | Q34433103 | ||
| Rapid development of vein graft atheroma in ApoE-deficient mice | Q35745654 | ||
| Mouse model of venous bypass graft arteriosclerosis | Q35753478 | ||
| Strain-dependent vascular remodeling phenotypes in inbred mice | Q35810132 | ||
| Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis | Q36095672 | ||
| Angiotensin II regulation of neuromodulation: downstream signaling mechanism from activation of mitogen-activated protein kinase | Q36257690 | ||
| Quantitative assessment of atherosclerotic lesions in mice | Q36456167 | ||
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | Q36548154 | ||
| Renin-angiotensin system and cardiovascular risk | Q36784673 | ||
| Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells | Q37011453 | ||
| Mouse strain-specific differences in vascular wall gene expression and their relationship to vascular disease. | Q40467248 | ||
| Models of experimental hypertension in mice. | Q41253768 | ||
| Heterodimerization and surface localization of G protein coupled receptors | Q41900573 | ||
| Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. | Q43957596 | ||
| G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. | Q44112454 | ||
| Advanced spin trapping of vascular nitric oxide using colloid iron diethyldithiocarbamate | Q44248733 | ||
| Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction | Q44578262 | ||
| Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs | Q46599371 | ||
| The essential role of MEKK3 signaling in angiotensin II-induced calcineurin/nuclear factor of activated T-cells activation | Q46673515 | ||
| Apelin protects myocardial injury induced by isoproterenol in rats | Q46796908 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells | Q47993319 | ||
| Gene transfer of a broad spectrum CC-chemokine inhibitor reduces vein graft atherosclerosis in apolipoprotein E-knockout mice. | Q50754865 | ||
| Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression. | Q53587076 | ||
| Angiotensin II and tumor necrosis factor-alpha upregulate survivin and Kruppel-like factor 5 in smooth muscle cells: Potential relevance to vein graft hyperplasia. | Q53605623 | ||
| Increased aortic stiffness in the insulin-resistant Zucker fa/fa rat. | Q53860774 | ||
| Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. | Q54141362 | ||
| NOX1 Deficiency Protects From Aortic Dissection in Response to Angiotensin II | Q59489724 | ||
| Functional expression of the seven-transmembrane HIV-1 co-receptor APJ in neural cells | Q73934633 | ||
| Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors | Q77215422 | ||
| Circulating Progenitor Cells Regenerate Endothelium of Vein Graft Atherosclerosis, Which Is Diminished in ApoE-Deficient Mice | Q79086919 | ||
| Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice | Q79948551 | ||
| Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system | Q80139145 | ||
| Direct effects of apelin on cardiomyocyte contractility and electrophysiology | Q80232618 | ||
| Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor | Q81134085 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 3343-54 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis | |
| P478 | volume | 118 |
| Q53051707 | A Tale of Two Elabela Null Mice. |
| Q36173903 | APJ acts as a dual receptor in cardiac hypertrophy |
| Q35082986 | APpEaLINg therapeutic target for obesity cardiomyopathy? |
| Q35048879 | AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II. |
| Q49030505 | Adipose tissue as regulator of vascular tone |
| Q34319305 | An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension |
| Q34451437 | Angiopoietins, abdominal aortic aneurysm and atherosclerosis |
| Q89006965 | Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology |
| Q34001678 | Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats. |
| Q88726706 | Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition |
| Q35166911 | Apelin and insulin resistance: another arrow for the quiver? |
| Q35573931 | Apelin and pulmonary hypertension. |
| Q36683179 | Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction |
| Q47146131 | Apelin as a novel drug for treating preeclampsia |
| Q37563582 | Apelin attenuates oxidative stress in human adipocytes. |
| Q34548928 | Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms |
| Q28237326 | Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms |
| Q37383989 | Apelin is a positive regulator of ACE2 in failing hearts. |
| Q30481616 | Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation |
| Q92689015 | Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs |
| Q37695588 | Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. |
| Q99587938 | Apelin signaling drives vascular endothelial cells towards a pro-angiogenic state |
| Q26823618 | Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system |
| Q46045920 | Apelin-36 Modulates Blood Glucose and Body Weight Independently of Canonical APJ Receptor Signaling |
| Q42868691 | Apelin-APJ signaling in retinal angiogenesis |
| Q37084945 | Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development |
| Q27010531 | Apelin-APJ signaling: a potential therapeutic target for pulmonary arterial hypertension |
| Q55635116 | Apelin/APJ axis improves angiotensin II-induced endothelial cell senescence through AMPK/SIRT1 signaling pathway. |
| Q36389929 | Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells--brief report |
| Q38225832 | Apelin/APJ system: a promising therapy target for hypertension |
| Q53468087 | Apelinergic System Structure and Function. |
| Q64987732 | Aplnra/b Sequentially Regulate Organ Left-Right Patterning via Distinct Mechanisms. |
| Q35625343 | Association of SNP Rs9943582 in APLNR with Left Ventricle Systolic Dysfunction in Patients with Coronary Artery Disease in a Chinese Han GeneID Population |
| Q35376926 | BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension |
| Q35971498 | Biological Significance of GPCR Heteromerization in the Neuro-Endocrine System |
| Q59127752 | Blockade of Rostral Ventrolateral Medulla Apelin Receptors Does Not Attenuate Arterial Pressure in SHR and -NAME-Induced Hypertensive Rats |
| Q90622980 | Cardiovascular response to small molecule APJ activation |
| Q37784108 | Cell communications in the heart. |
| Q37609624 | Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis |
| Q30397614 | Differential Contribution of Transmembrane Domains IV, V, VI, and VII to Human Angiotensin II Type 1 Receptor Homomer Formation |
| Q42715690 | Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor |
| Q50103826 | Disease severity impacts the relationship of apelin with arterial function in patients with rheumatoid arthritis. |
| Q35187029 | Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival |
| Q35040806 | Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension |
| Q57999809 | Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks |
| Q34276113 | ERG-APLNR axis controls pulmonary venule endothelial proliferation in pulmonary veno-occlusive disease |
| Q41945177 | Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure |
| Q47230975 | Effects of Apelin on Cardiovascular Aging |
| Q38344441 | Effects of apelin on the cardiovascular system. |
| Q45973849 | Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. |
| Q90341107 | Elabela Antagonizes Intrarenal Renin-Angiotensin System to Lower Blood Pressure and Protects Against Renal Injury |
| Q33608219 | Emerging Metabolic Therapies in Pulmonary Arterial Hypertension |
| Q37430874 | Endogenous regulation of cardiovascular function by apelin-APJ. |
| Q47806448 | Endothelial APLNR regulates tissue fatty acid uptake and is essential for apelin's glucose-lowering effects |
| Q37624930 | Endothelium as a gatekeeper of fatty acid transport |
| Q37052894 | FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. |
| Q38914050 | Functional Heterogeneity of Nadph Oxidases in Atherosclerotic and Aneurysmal Diseases |
| Q34630128 | Functional enhancement of AT1R potency in the presence of the TPαR is revealed by a comprehensive 7TM receptor co-expression screen |
| Q57823442 | G-Protein-Coupled Receptors in Heart Disease |
| Q41268751 | GPCR heterodimers: asymmetries in ligand binding and signalling output offer new targets for drug discovery. |
| Q34571568 | Heterodimerization of apelin receptor and neurotensin receptor 1 induces phosphorylation of ERK(1/2) and cell proliferation via Gαq-mediated mechanism |
| Q54112704 | Hydrostatic pressure suppresses fibrotic changes via Akt/GSK-3 signaling in human cardiac fibroblasts. |
| Q34467542 | Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling |
| Q95266037 | Impact of Apelin-13 on the Development of Coronary Artery Ectasia |
| Q33166766 | In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope |
| Q27314529 | In vivo modulation of endothelial polarization by Apelin receptor signalling |
| Q93161720 | International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand |
| Q86815048 | Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension |
| Q47161538 | Lack of association between the APLNR variant rs9943582 with ischemic stroke in the Chinese Han GeneID population |
| Q61799592 | Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling |
| Q35653311 | Mechanisms of thrombosis in obesity |
| Q33731819 | MiR-125b Is Critical for Fibroblast-to-Myofibroblast Transition and Cardiac Fibrosis |
| Q24305799 | MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion |
| Q24624403 | MicroRNA-26a is a novel regulator of vascular smooth muscle cell function |
| Q34116830 | Modulation of the apelin/APJ system in heart failure and atherosclerosis in man |
| Q88101582 | Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections |
| Q38199982 | New concepts in white adipose tissue physiology |
| Q38194082 | New concepts in white adipose tissue physiology. |
| Q34038044 | Oxidative stress and metabolic pathologies: from an adipocentric point of view. |
| Q35145481 | Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. |
| Q37671282 | Perivascular fat, AMP-activated protein kinase and vascular diseases. |
| Q47855918 | Plasma apelin level in patients with restless legs syndrome and its association with periodic leg movements |
| Q38938652 | Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin. |
| Q24631740 | Receptor heteromerization and drug discovery |
| Q64226623 | Receptor-Receptor Interactions as a Widespread Phenomenon: Novel Targets for Drug Development? |
| Q27691400 | Regulation of vascular tone by adipocytes |
| Q33742305 | Role of the Vasopressin/Apelin Balance and Potential Use of Metabolically Stable Apelin Analogs in Water Metabolism Disorders. |
| Q36030356 | Serum apelin is associated with left ventricular hypertrophy in untreated hypertension patients |
| Q92690983 | Systemic Outcomes of (Pyr1)-Apelin-13 Infusion at Mid-Late Pregnancy in a Rat Model with Preeclamptic Features |
| Q42124925 | Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges. |
| Q39129323 | The Role of Adipocytokines in Coronary Atherosclerosis |
| Q41268689 | The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition |
| Q36973488 | The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR. |
| Q47111154 | The mechanism of all-trans retinoic acid in the regulation of apelin expression in vascular endothelial cells |
| Q42158176 | The role of apelin on the alleviative effect of Angiotensin receptor blocker in unilateral ureteral obstruction-induced renal fibrosis |
| Q92241796 | Underlying Genes Involved in Atherosclerotic Macrophages: Insights from Microarray Data Mining |
| Q38954621 | Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease |
| Q33906868 | Upregulation of the apelin-APJ pathway promotes neointima formation in the carotid ligation model in mouse |
| Q88882223 | Vascular effects of apelin: Mechanisms and therapeutic potential |
| Q42540515 | Why don't they beat?: Cripto, apelin/APJ, and myocardial differentiation |
| Q37670483 | [Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. |
Search more.